Y Intercept Hong Kong Ltd Takes $680,000 Position in KalVista Pharmaceuticals, Inc. $KALV

Y Intercept Hong Kong Ltd acquired a new stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) during the first quarter, HoldingsChannel reports. The firm acquired 33,776 shares of the specialty pharmaceutical company’s stock, valued at approximately $680,000.

Several other institutional investors have also bought and sold shares of KALV. Tudor Investment Corp ET AL acquired a new stake in KalVista Pharmaceuticals in the third quarter worth about $24,360,000. Vestal Point Capital LP increased its stake in KalVista Pharmaceuticals by 152.0% during the 4th quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock valued at $30,524,000 after buying an additional 1,140,000 shares during the period. Parkman Healthcare Partners LLC raised its position in shares of KalVista Pharmaceuticals by 155.5% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock worth $21,132,000 after buying an additional 1,055,940 shares in the last quarter. Ameriprise Financial Inc. raised its position in shares of KalVista Pharmaceuticals by 2,258.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 945,125 shares of the specialty pharmaceutical company’s stock worth $10,685,000 after buying an additional 905,053 shares in the last quarter. Finally, Elmind Capital LP acquired a new stake in shares of KalVista Pharmaceuticals in the 4th quarter worth approximately $12,941,000.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on KALV. Needham & Company LLC cut shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, April 30th. Wall Street Zen raised KalVista Pharmaceuticals to a “hold” rating in a report on Saturday, June 13th. Leerink Partners downgraded KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. JonesTrading lowered KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, April 30th. Finally, Citizens Jmp cut KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Three research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, KalVista Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $33.25.

KalVista Pharmaceuticals Price Performance

Shares of NASDAQ KALV opened at $27.00 on Tuesday. KalVista Pharmaceuticals, Inc. has a twelve month low of $9.83 and a twelve month high of $27.00. The company has a current ratio of 5.17, a quick ratio of 5.10 and a debt-to-equity ratio of 8.18. The company has a market capitalization of $1.44 billion, a price-to-earnings ratio of -7.80 and a beta of -0.12. The firm has a 50-day moving average of $26.90 and a two-hundred day moving average of $20.54.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings data on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The firm had revenue of $40.86 million for the quarter, compared to the consensus estimate of $39.03 million. As a group, analysts expect that KalVista Pharmaceuticals, Inc. will post -1.19 earnings per share for the current fiscal year.

Insider Buying and Selling at KalVista Pharmaceuticals

In related news, insider Paul K. Audhya sold 2,239 shares of the stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $26.78, for a total transaction of $59,960.42. Following the completion of the sale, the insider directly owned 150,260 shares of the company’s stock, valued at $4,023,962.80. This represents a 1.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Brian Piekos sold 1,489 shares of the firm’s stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $26.78, for a total transaction of $39,875.42. Following the sale, the chief financial officer owned 21,661 shares of the company’s stock, valued at $580,081.58. The trade was a 6.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 39,971 shares of company stock valued at $965,493 in the last ninety days. Company insiders own 4.30% of the company’s stock.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.